EDIT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ED

Mkt Cap

$361.7M

Volume

1.29M

Next Earnings

November 9th

Loading chart

ED

EDITEditas Medicine, Inc. Common Stock

EDIT

Pay with—

Available Balance0.00

ED

Mkt Cap

$374.7M

Volume

1.29M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

EDIT Set to Begin First-in-Human Study in HypercholesterolemiaEditas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027.Zacks Investment Research · Oct 9, 2026

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical OfficerEditas Medicine announced the appointment of Dan Ory, M.D., as Chief Medical Officer effective September 8, 2026. Dr. Ory brings over 25 years of experience in cardiovascular and genetic medicine, previously serving as CMO at Arbor Biotechnologies and Casma Therapeutics. He will oversee clinical development strategy as Editas advances EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia treatment, toward clinical trials.GlobeNewswire Inc. · Sep 8, 2026

Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal DiseasesLyora Therapeutics, a new biotech company focused on genetic medicines for inherited retinal diseases, launched with $2.5 million in seed funding. The company's lead programs include LYA-101 for retinitis pigmentosa and LYA-102 for Usher Syndrome Type 2, with plans to submit an IND for LYA-101 within 18 months. The company is led by experienced executives from major genetic medicine firms and co-founded by renowned ophthalmology researchers.GlobeNewswire Inc. · Jul 14, 2026

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastThe global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.GlobeNewswire Inc. · Jul 3, 2026

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthThe CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.GlobeNewswire Inc. · Jul 3, 2026

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.The Motley Fool · May 31, 2026

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerNeutrolis Inc., a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases, announced the appointment of Caren Deardorf as Chief Business & Strategy Officer. Deardorf brings over 30 years of executive leadership experience in commercialization and product launches, previously serving as Chief Commercial & Strategy Officer at Editas Medicine, Magenta Therapeutics, and Ohana Biosciences. She will lead business development and commercial strategy as Neutrolis advances its NTR-1011 candidate following positive Phase 1a results.GlobeNewswire Inc. · Apr 15, 2026

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business UpdatesEditas Medicine reported Q4 2025 financial results with a net loss of $5.6 million ($0.06 per share), down from $45.4 million in Q4 2024. The company's lead candidate EDIT-401 demonstrated >90% mean LDL-C reduction in preclinical studies and remains on track for IND/CTA submission by mid-2026, with first-in-human trials in HeFH patients expected to begin later in 2026. The company maintains a strong cash position with runway into Q3 2027.GlobeNewswire Inc. · Mar 9, 2026

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment TrendsThe global genome editing market is projected to grow from $9.39 billion in 2025 to $23.66 billion by 2031, driven by increased funding, CRISPR advancements, and AI integration. However, off-target effects and regulatory hurdles pose significant challenges. Key developments include AI-enhanced editing systems achieving 95% reduction in off-target effects and expansion into agricultural biotechnology.GlobeNewswire Inc. · Jan 22, 2026

Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.GlobeNewswire Inc. · Nov 17, 2025

to start trading

ED

EDITEditas Medicine, Inc. Common Stock

EDIT

Pay with—

Available Balance0.00

Your PositionYou don't own any EDIT yet.

Related Tickers

Earnings